FDA OKs 1st mRNA Flu Shot, A New Era in Influenza Vaccination Begins with Moderna’s mFLUSIVA

floriparesort.com – 06 August 2026 | The FDA OKs 1st mRNA flu shot, marking a significant milestone in the development of influenza vaccines. Moderna’s mFLUSIVA has received approval from the U.S. Food and Drug Administration (FDA) for use in all adults 50 years and older. The FDA OKs 1st mRNA flu shot, a decision that could potentially revolutionize the way we approach flu vaccination. mFLUSIVA is the first mRNA-based flu vaccine to receive FDA approval, and it is expected to provide an important new option for America’s seniors. The FDA OKs 1st mRNA flu shot, and this approval is based on data from a late-stage trial involving more than 40,000 adults aged 50 and older, which showed that the shot was 26.6% more effective than a licensed standard-dose flu vaccine.

The FDA OKs 1st mRNA flu shot, and this decision has been welcomed by Moderna, the company behind the vaccine. “The FDA approval of mFLUSIVA, our fourth approved product in the United States and the first mRNA-based flu vaccine, demonstrates the continued strength and versatility of our mRNA platform,” said Stéphane Bancel, Chief Executive Officer of Moderna. The FDA OKs 1st mRNA flu shot, and this approval reflects the ongoing potential of Moderna’s mRNA platform to help address important public health challenges through continued scientific innovation.

mFLUSIVA is expected to be available for eligible populations in the U.S. for the 2026-2027 respiratory virus season, alongside other vaccines from Moderna. The FDA OKs 1st mRNA flu shot, and this approval is a significant step forward in the development of new and innovative flu vaccines. The vaccine uses mRNA technology to prompt the body to produce influenza antigens and trigger an immune response, an approach that could potentially allow faster updates to match circulating strains.

The FDA OKs 1st mRNA flu shot, and this decision is expected to have a significant impact on the way we approach flu vaccination. With the approval of mFLUSIVA, Moderna is now a major player in the flu vaccine market, competing with other companies such as Sanofi, GSK, and AstraZeneca. The FDA OKs 1st mRNA flu shot, and this approval is a testament to the power of mRNA technology in developing new and innovative vaccines.

In conclusion, the FDA OKs 1st mRNA flu shot, marking a new era in influenza vaccination. Moderna’s mFLUSIVA is a significant step forward in the development of new and innovative flu vaccines, and it is expected to provide an important new option for America’s seniors. The FDA OKs 1st mRNA flu shot, and this approval reflects the ongoing potential of Moderna’s mRNA platform to help address important public health challenges through continued scientific innovation.

Baca Juga

FDA Panel Backs mRNA Shot For Flu Season, A Historic Decision

Baca Juga

New Screwworm Cases in TX: Flesh-Eating Parasite Spreads Across Texas

Baca Juga

Allergy Medicine Recalled [titlebase]: Understanding the Risks and Consequences